TapImmune, Inc., a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, is celebrating the month of October by reinforcing its efforts to prevent and cure breast and ovarian cancer.
In an open letter posted on the TapImmune website, the company’s Chairman and CEO, Glynn Wilson, Ph. D, paid tribute to friends and loved one’s who have been affected by cancer during National Breast Cancer Awareness Month.
Breast cancer is the most common cancer among women in the United States. Every two minutes a woman in the U.S. is diagnosed with breast cancer and approximately 40,500 are expected to die this year from the disease.
According to Wilson, over the past year there has been growing evidence that the approach of immuno-oncology, that stimulates the body’s own immune system, will be a major force in the treatment of breast cancer.
TapImmune is making important progress in its development of T-cell vaccines for the treatment of breast and ovarian with the initiation of multiple Phase II clinical trials to determine the efficacy of its vaccines. The company’s Phase II clinical trial in triple negative breast cancer is recruiting a total of 80 patients at eight different clinical centers in the U.S. and the first patients have already been treated.
“Immuno- therapy is now perceived in the medical community as the most promising treatment for cancer,” said Glynn Wilson, Ph. D, Chairman and CEO, TapImmune. “We are proud to be at the forefront of immuno-oncology for breast cancer treatment and we are encouraged by our recent clinical progress. For us, we start National Breast Cancer Awareness Month in 2016 with renewed purpose towards our ultimate goal to save lives in indications that are in great need of new therapies.”
To view the full press release, click here.
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!
Filed Under: Drug Discovery